Search results

Yes, I think the concept was quite muddled here. The measure of 'stress' was a visual analogue scale, so presumably something like, 'on a scale of 1 top 10, how stressed do you feel?'. And they seemed to do things that they thought would specifically increase psychosocial stress including...

https://www.wgtn.ac.nz/health/centres/health-services-research-centre/recent-projects/long-covid-collective "Long COVID Collective A platform for collaboration between researchers, professionals and those with lived experiences of Long COVID to drive the future direction of health delivery...

Methods Results Keyword 'Stress' was measured. There wasn't anything interesting enough to say about stress in the Results section of the abstract. But still, of all the possible key words, 'stress' made the cut.

Thanks @Simone, very helpful.

Posts about the future of Cochrane in Norway (e.g. home institution and funding) have been moved to News from Cochrane

This platform looks pretty impressive - a combined personal data tracking app with patient registry. Interesting.

@Simone, when it says 'building on the You+ME registry', what does that mean? If people are already registered with the Australian version of that registry, do they need to re-register? Will that existing data remain in the registry? Is there are ongoing connection with the US You+ME registry...

A number of posts discussing Professor Esther Crawley have been moved to United Kingdom: Bath paediatric CFS clinic - Esther Crawley; Phil Hammond

And there seems to be an assumption that these 9 women, presumably in the UK, are sufficient to speak for all middle aged women managing their long COVID symptoms. Why don't researchers feel obliged to describe their sample in the abstract, and take care in extrapolations beyond it? I only got...

(cross post with Dolphin) It's a good question to investigate. These researchers seemed inclined to find no second-day decline. This makes me suspect that they may not understand what PEM looks like. With only 11 patients, this was not a big sample. The very high mean BMI makes me wonder...

Thank you very much to Millions Missing Belgique, a World ME Alliance member, for supporting the open letter and promoting the petition.

That abstract doesn't look very convincing. No mention of how many participants, no figures. They measured a whole lot of stuff, didn't seem to find much, had to fish around in subsets and, correlations between things and 'the number of symptoms during the acute infection', still in a subset...

If anyone can help us reach out to a Finnish organisation, that would be wonderful.

A reminder that, if you have a spare moment, liking some of the comments could give encouragement to people, and bring the best comments to the top. Thanks to Peter Trewhitt for responding to posts in the discussion under updates.

Just noting this Judges wowed by long-serving professor’s qualities of ingenuity, humility, generosity https://www.auckland.ac.nz/en/news/2021/06/29/judges-wowed-by-long-serving-professor.html This feels very much from the UK BPS playbook - very much 'establishment', effort spent pursuing...

I sent a version of the letter off today, attached here. I'll delete earlier versions on the thread to prevent confusion. I've also sent it to people involved in the health system in my region that I know, including people linked with HealthPathways, so hopefully that will be one step towards...

Mammoth tripe

Argh. Mammoth Study - doesn't that sound offensive? Short story: So they did the study, at that ridiculously great (mammoth) expense, found it didn't work, but of course claimed success anyway. When will the madness stop? We don't seem to have a thread on it yet: Maintaining musculoskeletal...

Here's an update on petition numbers - hopefully that's the start of a bit of a resurgence in signing. And here's the latest petition update:

There's a trial in ClinicalTrials: NCT05181683 COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers It's a Phase 1 trial and it ran from 7 Jan 2022 to 3 Jun 2022. 45 people were...